HC Wainwright Forecasts FibroBiologics Q1 Earnings

FibroBiologics Inc. (NASDAQ:FBLG) – HC Wainwright issued their Q1 2026 earnings per share estimates for FibroBiologics in a research note issued on Wednesday, November 5th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.11) EPS and Q4 2026 earnings at ($0.12) EPS.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings data on Friday, October 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03).

FBLG has been the subject of a number of other reports. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of FibroBiologics in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, FibroBiologics has a consensus rating of “Moderate Buy” and an average target price of $12.33.

FibroBiologics Trading Up 5.1%

Shares of FBLG opened at $0.35 on Thursday. The firm’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.66. The firm has a market capitalization of $18.13 million, a price-to-earnings ratio of -0.73 and a beta of -0.72. FibroBiologics has a 1-year low of $0.32 and a 1-year high of $3.76.

Hedge Funds Weigh In On FibroBiologics

Several large investors have recently made changes to their positions in FBLG. AQR Capital Management LLC bought a new stake in shares of FibroBiologics in the 1st quarter worth approximately $29,000. XTX Topco Ltd raised its stake in FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after buying an additional 28,276 shares during the last quarter. Ethos Financial Group LLC raised its stake in FibroBiologics by 100.0% during the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after buying an additional 24,424 shares during the last quarter. Nuveen LLC bought a new stake in FibroBiologics in the first quarter worth $31,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of FibroBiologics in the second quarter worth $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.